Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secreted protein… Read More
Abstract Dynamic Contrast-Enhanced MRI (DCE-MRI) is increasingly in use as an investigational biomarker of response in cancer clinical studies. Proper registration of images acquired at different time-points is essential for deriving diagnostic information from quantitative pharmacokinetic analysis of these data.… Read More
Abstract Brain metastasis (BM) can affect ~25% of non-small cell lung cancer (NSCLC) patients during their lifetime. Efforts to characterize patients that will develop BM have been disappointing. microRNAs (miRNAs) regulate the expression of target mRNAs. miRNAs play a role… Read More
Abstract: This paper reports the development of a biodosimetry device suitable for rapidly measuring expression levels of a low-density gene set that can define radiation exposure, dose and injury in a public health emergency. The platform comprises a set of… Read More
Abstract: MicroRNAs are small non-coding RNAs of 21-25 nucleotides that might impact regulatory mechanisms in cancer. Due to their influence on cell physiology, alteration of miRNA regulation can be implicated in carcinogenesis and disease progression. In general, one miRNA is… Read More
In a recent issue of Science , Olive and colleagues document that inhibition of Hedgehog (Hh) signaling in a genetically engineered mouse model of pancreatic cancer can enhance the intratumor concentration of certain anticancer drugs. Could this finding provide us… Read More
OBJECTIVE. We describe the significance of detecting focal areas of hypermetabolism in the breast in patients undergoing PET/CT for reasons other than for breast cancer detection or staging. CONCLUSION. When evaluated, almost all of the abnormal foci detected in the… Read More
Imaging to Cure Cancer: Valuable Contribution of Radiology for Clinical Trial Success
Written by Dr. Ron Korn, Founder, Chairman and Chief Medical Officer at Imaging Endpoints
“I keep dreaming of a future, a future with a long and healthy life, not lived in the shadow of cancer but in the light” – Patrick Swayze
Pancreatic cancer is one of the most lethal malignancies. It is often found late after the disease has spread throughout the body because it doesn’t cause symptoms until the disease has grown large. In fact, up to half of all patients with pancreatic cancer are found during an emergency room visit for sudden onset of jaundice (yellowing of eyes and skin). This usually prompts the treating physician to order a CT scan to look for a pancreatic tumor that may be causing the symptoms.
Industrial Development Authority of Scottsdale awards funding to Scottsdale Healthcare Research Institute
A one-of-a-kind rapid cancer detection program developed through collaboration between local physicians, the Scottsdale Healthcare Research Institute and Virginia G. Piper Cancer Center at Scottsdale Healthcare has been awarded a $100,000 grant from the Industrial Development Authority (IDA) of Scottsdale.
The Rapid Detection and Assessment of Response (RADAR) program uses high-tech radiologic imaging and advanced analysis to quickly assess whether a tumor is responding to treatment. RADAR provides physicians with information to make timely decisions about a treatment’s effectiveness and whether an alternate treatment is appropriate, according to Ronald Korn, M.D., PhD., medical director of Scottsdale Healthcare’s Virginia G. Piper Cancer Center.